Harrow, Inc. Common Stock

HROWNASDAQ • USD
29.31 USD
↗ 0.22 (0.76%)🟢LIVE (AS OF 11:49 AM EST)
🟢Market: OPEN

Harrow, Inc. Common Stock (HROW) trades at $29.31 per share. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". This is driven by negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, HROW trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Nov 16, 2026.

Open?$29.00
High?$29.67
Low?$28.81
Prev. Close?$29.09
Volume?141.4K
Avg. Volume?694.5K
VWAP?$29.38
Rel. Volume?0.20x
Bid / Ask
Bid?$25.32 × 100
Ask?$33.58 × 100
Spread?$8.26
Midpoint?$29.45
Valuation & Ratios
Market Cap?1.1B
Shares Out?37.5M
Float?30.8M
Float %?82.2%
P/E Ratio?N/A
P/B Ratio?37.41
EPS?-$0.76
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Employees
373
Market Cap
1.1B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2007-04-30
Address
1A BURTON HILLS BLVD
NASHVILLE, TN
Phone: 615.733.4731
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
36
Momentum?
85
Short Sent.?
24
Piotroski F-Score?6/9Mixed
Altman Z-Score?2.01Grey
Confidence?59%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?23.03%Squeeze Risk
Short Interest?7.1M
Days to Cover?14.1
Free Float30.8M
Avg Daily Volume502.1K
Settlement Date2026-10-30
Financial Health
Current Ratio?2.29Strong
Quick Ratio?2.12Strong
Cash Ratio?0.66Adequate
Debt/Equity?10.03High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
37.41HIGH▾
P/S?
Peers
100
S&P
43
3.60FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
3
80.1HIGH▾
EV/Sales?
Peers
100
S&P
43
4.32FAIR▾
Returns & Efficiency
ROE?
S&P
3
-97.6%WEAK▾
ROA?
S&P
3
-6.4%WEAK▾
Cash Flow & Enterprise
FCF?$-20353000
Enterprise Value?$1.3B
Fundamentals ratios updated end of day